Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the safety and potential effectiveness of CCX140-B in subjects with Type 2 diabetes mellitus.
The primary objective of this study is to evaluate the safety and tolerability of CCX140-B in subjects with Type 2 diabetes mellitus (T2DM) based on subject incidence of adverse events. The secondary objectives of this study include evaluation of the effect of CCX140-B on several measures of effectiveness commonly used in the evaluation of diabetes medications. Study acquired by Amgen and all disclosures were done by previous sponsor ChemoCentryx.
Age
18 - 70 years
Sex
ALL
Healthy Volunteers
No
Auchenflower, Queensland, Australia
Kippa-Ring, Queensland, Australia
Beroun, Czechia
Hlučín, Czechia
Neratovice, Czechia
Nový Jičín, Czechia
Ostrava, Czechia
Pardubice, Czechia
Prague, Czechia
Přelouč, Czechia
Start Date
January 1, 2010
Primary Completion Date
October 1, 2010
Completion Date
November 1, 2010
Last Updated
March 6, 2025
159
ACTUAL participants
Placebo
DRUG
pioglitazone
DRUG
CCX140-B
DRUG
CCX140-B
DRUG
Lead Sponsor
Amgen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07433062